A 60-year-old man, Mr. Bakare Buraimoh, has been sentenced to six months imprisonment at the Ilaro Correctional Centre, Ogun State, for assaulting a staff of Ikeja Electric (IE)
The Ifo Magistrate Court delivered the judgment against Buraimoh, a resident of Isheri-Olofin community, for assaulting Abiodun Fakoya, a staff of IE attached to its Olowora Undertaking Office.
In the judgment delivered by Magistrate A. I. Arogundade, the accused was found guilty of the offence and thereafter sentenced to six months imprisonment with option of N100, 000 fine.
While reacting to the judgment, the Head of Corporate Communications, Ikeja Electric, Mr. Felix Ofulue, said the decision to seek redress in court over attack on the staff of the company is to stem the menace as he hoped this will serve as a deterrent to other offenders against future reoccurrence.
Seelos Therapeutics, Inc. a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which includes the exercise in full by the underwriter of its option to purchase …
– Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, announced today the closing of its previously announced underwritten public offering of 17,530,488 shares of its common stock, at a price to the public of $2.05 per share, which includes the exercise in full by the underwriter of its option to purchase up to 2,286,585 additional shares of common stock. The net proceeds to Seelos from this offering are expected to be approximately $33.
Sartorius Stedim Biotech with exceptionally strong growth in 2020 and a further increase in profitability
USA - English
- Sartorius Stedim Biotech plays a key role as a provider of essential technologies for vaccine production
- Number of employees rises by 21.6 percent to more than 7,500
- Strong outlook for 2021: Sales revenue set to grow by 20 percent to 26 percent
- Group management raises sales target for 2025 to 4 billion euros
News provided by
Share this article
Share this article
AUBAGNE, France, Jan. 27, 2021 /PRNewswire/ Sartorius Stedim Biotech, a leading partner of the biopharma industry, recorded exceptionally strong growth in 2020 that was driven by strong organic development, several acquisitions and additional momentum from business related to the coronavirus pandemic. According to preliminary figures, the Group closed the year with significant double-digit growth rates in sales revenue, order intake and earnings, recording further gains across all geograph
It looks like this was the result of either:
A mistyped address
A broken link on our site
A broken link on a search engine results page
A broken link on someone else s page
Some things to try:
Use the navigation menu at the top Most Read